Fertility & Reproductive Health

Fertility challenges affect millions of individuals and couples worldwide and may arise from a wide spectrum of physiological, genetic, hormonal, immunological, or environmental factors. These challenges can impact either partner, which is why a balanced and thorough diagnostic approach is essential. At Labassure, we offer a comprehensive suite of diagnostic solutions to evaluate and support reproductive health in both men and women, recognizing that fertility is a shared responsibility.

‍

Our Fertility & Reproductive Health portfolio integrates advanced laboratory technologies with clinically validated protocols to assess key aspects of reproductive function. This includes hormonal evaluations, ovarian reserve testing, genetic screening, and semen analysis, alongside infection panels relevant to reproductive tract health.

In addition to standard assessments, Labassure offers specialized services such as

Endometrial Receptivity Testing (ORA), a non-invasive molecular assay that evaluates the optimal window for embryo implantation—particularly useful in IVF cycles and cases of recurrent implantation failure.
Preimplantation Genetic Testing (PGT), which enables the screening of embryos created through IVF for chromosomal aneuploidies or specific inherited conditions prior to implantation. PGT supports embryo selection by identifying those most likely to result in a successful pregnancy, thereby improving implantation rates and reducing the risk of miscarriage or genetic disease transmission.

These diagnostic tools are designed to assist fertility specialists, reproductive endocrinologists, and IVF practitioners in identifying root causes of infertility, personalizing treatment plans, and supporting informed reproductive decision-making at every stage of the fertility journey.

‍

Our Fertility & Reproductive Health portfolio integrates:

Preimplantation Genetic Testing (PGT)

Pre-Implantation Genetic Testing (PGT)—which includes both PGT-A and PGT-M that allows for the genetic assessment of embryos before implantation, offering invaluable insight and control in assisted reproductive technology (ART).

Chromosomal abnormalities are one of the most common reasons for failed IVF cycles, recurrent pregnancy loss, and congenital disorders. PGT enables clinicians to screen embryos for chromosomal or inherited genetic conditions before transfer—thereby increasing the chances of a successful pregnancy and reducing the emotional and financial toll of repeated IVF cycles.
‍

How PGT Works:

‍

IVF Cycle: Embryos are created via standard IVF procedures.
Embryo Biopsy: A few cells are gently extracted from the outer layer of the embryo (trophectoderm) on day 5 or 6. The embryo remains safe and is cryopreserved.
Genetic Analysis: Labassure uses cutting-edge genomic technologies to analyze the extracted cells for chromosomal or genetic abnormalities.
Embryo Selection & Transfer: Genetically healthy embryos with the highest implantation potential are selected for transfer or stored for future use.

‍

Key Benefits:

‍

Higher Pregnancy Success Rates: Increases the likelihood of selecting a viable embryo.
Lower Miscarriage Risk: Reduces the chances of failed implantation due to chromosomal abnormalities.
Fewer IVF Cycles Needed: Enables more efficient treatment planning with fewer attempts.
Safe Single Embryo Transfer: Promotes healthy singleton pregnancies by reducing the need to transfer multiple embryos.
Targeted Disease Prevention: Prevents transmission of known inherited conditions in high-risk couples.
Personalized Fertility Strategy: Offers better control over embryo selection, optimizing outcomes based on genetic profile.

‍

Recommended For:
‍

Couples experiencing recurrent IVF failure or pregnancy loss
Individuals with a known genetic disorder or carrier status
Women of advanced maternal age
Cases of severe male factor infertility
IVF cycles involving donor gametes or surrogacy

‍

Labassure’s PGT services bring together precision diagnostics and reproductive medicine—offering hope, clarity, and greater control to couples pursuing their dream of parenthood.

‍

Screens embryos for an abnormal number of chromosomes, helping identify euploid (chromosomally normal) embryos. This improves implantation rates and reduces miscarriage risk.

Targets specific genetic mutations previously identified in the family. This test is especially useful for couples at risk of transmitting single-gene disorders like thalassemia, cystic fibrosis, or muscular dystrophy.

Download Brochure

Endometrial Receptivity Testing

ORA (Non-Invasive Endometrial Receptivity Assay) offers a cutting-edge, non-invasive method to assess endometrial receptivity—ensuring that embryo transfer is optimally timed for higher success rates in IVF cycles.
‍
Unlike traditional invasive biopsies, ORA uses a non-invasive RNA-based test from uterine fluid to evaluate the expression profile of genes associated with endometrial receptivity. This advanced molecular test minimizes patient discomfort while maximizing diagnostic accuracy.

Key Benefits:
‍

Non-Invasive Sampling: No biopsy required; utilizes uterine fluid, reducing risk and discomfort.
Personalized Window of Implantation (WOI): Determines the optimal time for embryo transfer based on individual endometrial gene expression.
Improved IVF Outcomes: Helps reduce implantation failure by aligning embryo transfer with the most receptive phase of the endometrium.
Reproducible and Reliable: Based on transcriptomic analysis, ensuring high sensitivity and specificity

Recommended For:
‍

Women with repeated implantation failure (RIF)
Patients undergoing IVF or frozen embryo transfer (FET)
Cases with unexplained infertility

Download Brochure

Fertility & Reproductive Health

In addition to standard assessments, Labassure offers specialized services such as

Download Brochure

Download Brochure

Corporate

Test & Services

Fertility & Reproductive Health

In addition to standard assessments, Labassure offers specialized services such as

PGT-A (Aneuploidy Screening)

PGT-M (Monogenic Disorder Testing)

Download Brochure

oraTM

Download Brochure

Corporate

Test & Services

ora^TM